Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: Association with estrogen receptor-α genotypes

Adarsh J. Sai, John Christopher G. Gallagher, Xiang Fang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. Methods: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. Results: In both intent-to-treat and complier (>80% adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P <0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P <0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P <0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P <0.05). Conclusions: ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs-PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.

Original languageEnglish
Pages (from-to)1101-1112
Number of pages12
JournalMenopause
Volume18
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Calcitriol
Estrogen Receptors
Genotype
Hormones
Lipids
Estrogens
Alleles
Single Nucleotide Polymorphism
Serum
LDL Lipoproteins
Placebos
Conjugated (USP) Estrogens
HDL Lipoproteins
Therapeutics
Medroxyprogesterone
Genes
VLDL Cholesterol
Controlled Clinical Trials
Group Psychotherapy
Progesterone

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women : Association with estrogen receptor-α genotypes. / Sai, Adarsh J.; Gallagher, John Christopher G.; Fang, Xiang.

In: Menopause, Vol. 18, No. 10, 10.2011, p. 1101-1112.

Research output: Contribution to journalArticle

@article{ee43e5fecf20499a9ed58c095011e626,
title = "Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: Association with estrogen receptor-α genotypes",
abstract = "Objective: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. Methods: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. Results: In both intent-to-treat and complier (>80{\%} adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P <0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P <0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P <0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P <0.05). Conclusions: ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs-PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.",
author = "Sai, {Adarsh J.} and Gallagher, {John Christopher G.} and Xiang Fang",
year = "2011",
month = "10",
doi = "10.1097/gme.0b013e318217d41d",
language = "English",
volume = "18",
pages = "1101--1112",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women

T2 - Association with estrogen receptor-α genotypes

AU - Sai, Adarsh J.

AU - Gallagher, John Christopher G.

AU - Fang, Xiang

PY - 2011/10

Y1 - 2011/10

N2 - Objective: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. Methods: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. Results: In both intent-to-treat and complier (>80% adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P <0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P <0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P <0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P <0.05). Conclusions: ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs-PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.

AB - Objective: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-α gene single nucleotide polymorphisms (ESR-α SNPs) on the response to therapy. Methods: A total of 489 postmenopausal women older than 65 years were enrolled into a 3-year double-blind, placebo-controlled clinical trial. Results: In both intent-to-treat and complier (>80% adherent) analysis, there was a significant increase in serum high-density lipoproteins and a significant decrease in serum low-density lipoproteins (LDLs) and the LDL/high-density lipoprotein ratio in all hormone treatment groups compared with placebo (P <0.05). However, serum triglycerides and very low-density lipoproteins increased in the EPT and ET + calcitriol groups versus placebo (P <0.05). ESR-α SNPs PvuII and XbaI seemed to have a significant effect on the response to treatment. Genotypes containing the p allele showed a significantly greater decrease in serum cholesterol and very low-density lipoprotein than those having the P allele in the ET + calcitriol group (P <0.05), and those with the x allele had a significantly greater decrease in serum cholesterol in the hormone therapy + calcitriol group at the end of 3 years versus the X allele, and a greater decrease in serum LDL in alleles x versus the X in the ET + calcitriol group (P <0.05). Conclusions: ET with or without progesterone had a favorable effect on lipid profile in postmenopausal older women, and this was dependent on estrogen receptor SNPs-PvuII and XbaI. However, this interaction with ESR-α SNPs needs to be confirmed in larger studies.

UR - http://www.scopus.com/inward/record.url?scp=80053263600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053263600&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e318217d41d

DO - 10.1097/gme.0b013e318217d41d

M3 - Article

C2 - 21712736

AN - SCOPUS:80053263600

VL - 18

SP - 1101

EP - 1112

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 10

ER -